Rybelsus

Caloric Restriction, at least one weight-related comorbid condition, Obesity + 6 more

Treatment

6 FDA approvals

20 Active Studies for Rybelsus

What is Rybelsus

Semaglutide

The Generic name of this drug

Treatment Summary

Semaglutide is a medication used to treat type 2 diabetes. It belongs to a class of drugs called glucagon-like peptide 1 (GLP-1) analogs. It was approved by the FDA in 2017 and can be injected once a week or taken as a tablet once a day. Semaglutide activates the GLP-1 receptor, which stimulates insulin secretion and lowers blood glucose levels. It has been shown to reduce HbA1c levels and body weight in people with type 2 diabetes. In 2021, it was also approved for chronic weight management in adults with general obesity or overweight.

Ozempic

is the brand name

image of different drug pills on a surface

Rybelsus Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Ozempic

Semaglutide

2017

19

Approved as Treatment by the FDA

Semaglutide, commonly known as Ozempic, is approved by the FDA for 6 uses including Type 2 Diabetes Mellitus and Cardiovascular Events .

Type 2 Diabetes Mellitus

Cardiovascular Events

Type 2 Diabetes

Cardiovascular Diseases

Physical Activity

Used in combination with other therapies

Diet

Used in combination with other therapies

Effectiveness

How Rybelsus Affects Patients

Semaglutide helps reduce levels of sugar in the blood, lower blood pressure, and cause weight loss. It does this by increasing insulin production and decreasing the amount of the hormone glucagon, which is usually linked to higher blood sugar levels. Semaglutide also decreases the amount of bad cholesterol and triglycerides in the body. However, it can cause medullary thyroid cell carcinoma in rodents, so those with a family history should not take this drug. It can also lead to pancreatitis, dehydration, and slower digestion, so patients should make sure to stay hydrated and be aware of the effects of other drugs

How Rybelsus works in the body

Semaglutide helps to control blood sugar by stimulating the pancreas to produce insulin and reducing the amount of glucagon, a hormone that raises blood sugar. It binds to the GLP-1 receptor and triggers other effects that help lower blood sugar. It also helps reduce the progression of atherosclerosis and can lead to weight loss by decreasing appetite and cravings.

When to interrupt dosage

The quantity of Rybelsus is contingent upon the determined condition, including Type 2 Diabetes, at least one weight-related comorbidity and reduced-calorie diet. The extent of dosage is subject to the mode of delivery (e.g. Solution - Subcutaneous or Subcutaneous) as noted in the table below.

Condition

Dosage

Administration

Obesity

, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL

Solution - Subcutaneous, Solution, Subcutaneous, , Injection, solution, Injection, solution - Subcutaneous, Tablet - Oral, Oral, Tablet, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension

Physical Activity

, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL

Solution - Subcutaneous, Solution, Subcutaneous, , Injection, solution, Injection, solution - Subcutaneous, Tablet - Oral, Oral, Tablet, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension

Type 2 Diabetes

, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL

Solution - Subcutaneous, Solution, Subcutaneous, , Injection, solution, Injection, solution - Subcutaneous, Tablet - Oral, Oral, Tablet, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension

Diet

, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL

Solution - Subcutaneous, Solution, Subcutaneous, , Injection, solution, Injection, solution - Subcutaneous, Tablet - Oral, Oral, Tablet, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension

Chronic Weight Management therapy

, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL

Solution - Subcutaneous, Solution, Subcutaneous, , Injection, solution, Injection, solution - Subcutaneous, Tablet - Oral, Oral, Tablet, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension

Cardiovascular Diseases

, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL

Solution - Subcutaneous, Solution, Subcutaneous, , Injection, solution, Injection, solution - Subcutaneous, Tablet - Oral, Oral, Tablet, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension

Caloric Restriction

, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL

Solution - Subcutaneous, Solution, Subcutaneous, , Injection, solution, Injection, solution - Subcutaneous, Tablet - Oral, Oral, Tablet, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension

at least one weight-related comorbid condition

, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL

Solution - Subcutaneous, Solution, Subcutaneous, , Injection, solution, Injection, solution - Subcutaneous, Tablet - Oral, Oral, Tablet, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension

Cardiovascular Events

, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL

Solution - Subcutaneous, Solution, Subcutaneous, , Injection, solution, Injection, solution - Subcutaneous, Tablet - Oral, Oral, Tablet, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension

Warnings

Rybelsus Contraindications

Condition

Risk Level

Notes

Multiple Endocrine Neoplasia

Do Not Combine

Thyroid Neoplasms

Do Not Combine

Medullary carcinoma of thyroid

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Semaglutide may interact with Pulse Frequency

There are 20 known major drug interactions with Rybelsus.

Common Rybelsus Drug Interactions

Drug Name

Risk Level

Description

Acetohexamide

Moderate

Semaglutide may increase the hypoglycemic activities of Acetohexamide.

Carbutamide

Moderate

Semaglutide may increase the hypoglycemic activities of Carbutamide.

Chlorpropamide

Moderate

Semaglutide may increase the hypoglycemic activities of Chlorpropamide.

Englitazone

Moderate

The risk or severity of hypoglycemia can be increased when Semaglutide is combined with Englitazone.

Fluconazole

Moderate

The risk or severity of hypoglycemia can be increased when Semaglutide is combined with Fluconazole.

Rybelsus Toxicity & Overdose Risk

People who take too much semaglutide (more than 4 mg in one dose) may experience nausea, although full recovery is expected. Patients should be monitored and given supportive care as needed, as the drug can remain in the body for up to one week. There is no specific antidote for an overdose of semaglutide.

image of a doctor in a lab doing drug, clinical research

Rybelsus Novel Uses: Which Conditions Have a Clinical Trial Featuring Rybelsus?

196 active studies are currently investigating the potential of Rybelsus to address Diseases and weight-related comorbidities, in individuals with a Body Mass Index >27 kg/m2.

Condition

Clinical Trials

Trial Phases

Physical Activity

30 Actively Recruiting

Not Applicable, Phase 2

Cardiovascular Diseases

0 Actively Recruiting

Type 2 Diabetes

185 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 1, Early Phase 1, Phase 3

Cardiovascular Events

4 Actively Recruiting

Not Applicable, Phase 4

at least one weight-related comorbid condition

0 Actively Recruiting

Chronic Weight Management therapy

0 Actively Recruiting

Caloric Restriction

0 Actively Recruiting

Obesity

0 Actively Recruiting

Diet

5 Actively Recruiting

Not Applicable, Phase 1

Rybelsus Reviews: What are patients saying about Rybelsus?

5

Patient Review

7/4/2022

Rybelsus for Type 2 Diabetes Mellitus

I've been taking 7mg for almost a year now and have seen some great results like losing 20lbs, lower blood sugar, and A1c. I also haven't experienced any negative side effects, which is amazing.

5

Patient Review

7/4/2022

Rybelsus for Type 2 Diabetes Mellitus

I've been taking 7mg of this medication for nearly a year and have seen some great results, like losing 20lbs and bringing my blood sugar down. My A1C is also down with no negative side effects!

5

Patient Review

8/29/2022

Rybelsus for Type 2 Diabetes Mellitus

I gradually increased my dosage over the course of three months and saw significant results. I lost 17 pounds without any negative side effects.

4.7

Patient Review

11/2/2022

Rybelsus for Type 2 Diabetes Mellitus

At first, this medication made me feel nauseous and I had no appetite. However, once I got used to it, it was much better. I also discovered that if you hold the pill in your mouth for too long, it has a really bitter taste (yuck). So my advice is to put the pill near the back of your tongue and quickly drink some water. In just three months, my A1C went from 8.2 to 6.4, and I lost six pounds in addition to taking 1000 mg Metformin.

4.3

Patient Review

9/13/2021

Rybelsus for Type 2 Diabetes Mellitus

I've had a lot of trouble in the past taking diabetic medication, but Rybellsus has been different. No upset stomach or urinary problems. Blood sugar is better controlled and I'm hoping to be moved up to 14mg soon.

4.3

Patient Review

7/18/2022

Rybelsus for Type 2 Diabetes Mellitus

I saw a significant drop in my blood sugar levels after taking this medication.

3.7

Patient Review

4/4/2022

Rybelsus for Type 2 Diabetes Mellitus

I've been taking rybelsus for three weeks now and have had no major issues. I will be upping my dosage to seven milligrams next week, and so far everything has been going well. The only thing I experienced at the beginning was slight lightheadedness, but that passed quickly.

3

Patient Review

5/11/2022

Rybelsus for Type 2 Diabetes Mellitus

I was using 3mg for a month and experiencing symptoms like bladderfulness and nausea. I increased the dosage to 7mg for the last 15 days, but the side effects are the same. The only difference is that my sugar levels have come down.

2.7

Patient Review

10/23/2021

Rybelsus for Type 2 Diabetes Mellitus

I had some normal side effects at first, but they got worse after a few days instead of better. I stopped taking the pill after 15 days because I couldn't handle the side effects anymore.

2.7

Patient Review

4/18/2022

Rybelsus for Type 2 Diabetes Mellitus

The smaller strength pills had no real effect on appetite. The largest dose caused extreme nausea and diarrhea. Could not eat to take nailing because I felt so sick. The should be other strengths

1.7

Patient Review

7/12/2022

Rybelsus for Type 2 Diabetes Mellitus

I started taking Rybelsus last year and again this year. No effect on weight loss, no effect on my blood sugar. I had stomach pain, heartbeat, constipation and lower back pain. After every 6 month I had problem with vomiting. I think Rybelsus give me Acute gallbladder disease. Every time I stop taking it, after a few days all the side effect was gone.I will never take it again. The biggest effect of Rybelsus was on my wallet

1.7

Patient Review

9/1/2022

Rybelsus for Type 2 Diabetes Mellitus

I have been taking Rybelsus for a year and a half at the 7 mg dosage. Unfortunately, it has made my life quite miserable. I experience terrible bloating, stomach pain, and gas on a regular basis. I've even lost around 40 pounds because of how little I can eat while on this medication. Additionally, it started giving me heart palpitations and is no longer effectively controlling my blood sugar levels - even when I consume very few carbs. So, I'm planning to speak with my doctor soon about finding an alternative treatment option.

1.7

Patient Review

6/7/2022

Rybelsus for Type 2 Diabetes Mellitus

This medication made me so sick after only the second dose. I had diarrhea, vomiting and nausea so bad that I couldn't move. I discontinued it right away. Of course you will lose weight if you can't keep food down.

1.7

Patient Review

6/22/2022

Rybelsus for Type 2 Diabetes Mellitus

My A1C readings did not budge after using this treatment, and if anything, my average daily glucose readings went up by over 150 points.

1.3

Patient Review

9/24/2022

Rybelsus for Type 2 Diabetes Mellitus

I'm on day four of the treatment, and I've been feeling a strong metallic taste in my mouth. Additionally, it feels like I was punched in my right kidney. If these symptoms don't improve by day seven, I'll be stopping the medication.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about rybelsus

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does the drug Rybelsus do?

"Rybelsus is a hormone that helps to lower blood sugar levels by mimicking the effects of the protein GLP-1, which is found naturally in the body and helps to control blood sugar levels."

Answered by AI

Is Rybelsus the same as metformin?

"A major difference between Rybelsus and metformin is that Rybelsus is a newer brand-name medication that isn't available as a generic yet, while metformin is available as a lower-cost generic."

Answered by AI

Is Rybelsus a weight loss pill?

"If you are an adult with type 2 diabetes, RYBELSUS® may be a medication option for you. This medication is intended to be used in conjunction with diet and exercise to improve blood sugar levels and A1C. Although weight loss is not a primary goal of this medication, some patients may experience weight loss as a side effect."

Answered by AI

How effective is Rybelsus for weight loss?

"Although Rybelsus is not explicitly marketed as a weight loss drug, many people report losing weight while taking it. On average, people lost 5 pounds (2.3 kg) while taking the 7 mg dose, and 8.1 pounds (3.7 kg) while taking the 14 mg dose. One of the ways Rybelsus is believed to work is by helping to make users feel full after a meal."

Answered by AI

Clinical Trials for Rybelsus

Image of Caridad Center, Inc. in Boynton Beach, United States.

CHW Nutrition Support for Type 2 Diabetes

18+
All Sexes
Boynton Beach, FL

This study tests whether adding CHW support to usual nutrition care helps adults with type 2 diabetes, hypertension, or chronic kidney disease manage their diet and health. At Caridad Center, a free clinic in Palm Beach County, Florida, usual care includes medical nutrition therapy from a registered dietitian and medically tailored groceries. Many patients find it hard to keep up dietary changes because of limited nutrition knowledge, cooking skills, food costs, and cultural fit. Two hundred adults will be randomly assigned to usual care or usual care plus INTEGRATE-CHW, a 12-week program of six sessions with a trained CHW. In each session the participant selects one or two goals from the dietitian's plan and builds an action plan with the CHW. The dietitian remains responsible for the nutrition plan. The study will compare nutrition self-efficacy, nutrition literacy, diet quality, food security, and clinical measures between groups at baseline and Week 12. It will also evaluate how well the program fits into routine clinic care.

Waitlist Available
Has No Placebo

Caridad Center, Inc.

Janet Diaz Martinez

Image of McMaster University in Hamilton, Canada.

Exercise for Gender Differences in BDNF Levels

18 - 35
All Sexes
Hamilton, Canada

A single bout of exercise can improve cognitive abilities like memory and attention. These functions help us navigate through everyday life. However, we do not fully understand how exercise improves cognitive abilities. We believe that exercise improves the brain by increasing the amount of BDNF in the blood. BDNF is very important for learning and memory. However, we still do not know if BDNF responds differently to exercise between females and males. The purpose of this work is to characterize potential sex-differences in the circulating BDNF response to acute exercise. We will test the hypothesis that males will have greater serum and plasma BDNF responses compared to females following a maximal exercise test.

Recruiting
Has No Placebo

McMaster University

Jeremy J Walsh, PhD

Image of Kaiser Permenante Division of Research in Pleasanton, United States.

EHR Alerts for Metabolic Syndrome

18+
All Sexes
Pleasanton, CA

SWAP-CKM (SWitching to Appropriate Prescription in Cardiovascular-Kidney-Metabolic Syndrome) is a pragmatic, cluster-randomized clinical trial designed to evaluate whether electronic health record (EHR)-based alerts can improve medication prescribing among adults with cardiovascular, kidney, and metabolic (CKM) conditions. The study will include all eligible adult patients receiving care within Kaiser Permanente Northern California (KPNC) who have CKM conditions and opportunities for therapeutic medication substitution. Fifteen service areas are randomly assigned to either an intervention group or a usual care group. Clinicians in the intervention group will receive EHR-based Best Practice Advisories (BPAs) identifying opportunities to replace potentially inappropriate medications with guideline-recommended therapies. The intervention may also include audit-and-feedback reports to support medication optimization. Clinicians retain full discretion over treatment decisions. The primary outcome is the proportion of eligible therapeutic optimization opportunities achieved at 9 months. Secondary outcomes include medication initiation and discontinuation, medication optimization at 18 months, and polypharmacy burden.

Waitlist Available
Has No Placebo

Kaiser Permenante Division of Research

Ankeet S Bhatt, MD, MBA, ScM

Have you considered Rybelsus clinical trials?

We made a collection of clinical trials featuring Rybelsus, we think they might fit your search criteria.
Go to Trials
Image of University of Cincinnati Medical Center in Cincinnati, United States.

Continuous Glucose Monitoring for Type 2 Diabetes

18+
All Sexes
Cincinnati, OH

The TRANSITION-CGM trial will evaluate whether starting continuous glucose monitoring (CGM) before hospital discharge improves blood glucose control in adults with type 2 diabetes compared with usual care using finger-stick blood glucose checks. The study focuses on the transition from hospital to home, when patients may face changes in diabetes medications and challenges managing their blood glucose levels. This single-center, randomized controlled trial will enroll approximately 218 adults with type 2 diabetes, a hemoglobin A1c (HbA1c) 9% and above, and treatment with insulin and/or oral diabetes medications. Participants will be recruited during hospitalization and must be expected to return home after discharge. People already using a CGM will not be eligible. Participants will be randomly assigned in equal numbers to one of two groups. The CGM group will start using a continuous glucose monitor before discharge and receive device training and written instructions. The usual-care group will continue finger-stick blood glucose monitoring and receive standard discharge education. Both groups will receive assistance with outpatient diabetes follow-up. Diabetes medications will be managed by treating clinicians according to usual clinical practice. Participants will be followed for approximately 12 weeks after discharge, with an early follow-up encounter and a final assessment at 12 weeks. The primary outcome is HbA1c at 12 weeks, a blood test that reflects average blood glucose levels over approximately three months. Secondary outcomes include diabetes-related hospitalizations and episodes of low blood sugar. Additional exploratory measures include CGM use, follow-up attendance, patient-reported experiences, and time spent within the target glucose range when CGM data are available. The study will determine whether initiating CGM during hospitalization can improve glycemic control after discharge and provide preliminary evidence about its effects on diabetes-related hospitalizations and hypoglycemia.

Waitlist Available
Has No Placebo

University of Cincinnati Medical Center

Arunab H Mehta, MD, MEd

Have you considered Rybelsus clinical trials?

We made a collection of clinical trials featuring Rybelsus, we think they might fit your search criteria.
Go to Trials
Image of Penn Medicine, 3535 Market St. in Philadelphia, United States.

Financial Counseling and Health Reviews for Chronic Illness Management

18+
All Sexes
Philadelphia, PA

Among adults with chronic illnesses like hypertension, diabetes, or HIV, adherence to daily oral medications is essential but often below 50%. Why do medication adherence and preventive health service engagement remain stubbornly low? Scarcity theory offers a novel explanation in the context of poverty. It posits that economic hardship imposes a cognitive burden that shifts attention from long-term goals to immediate needs, reduces future orientation (the relative value placed on immediate vs. future outcomes), and limits mental bandwidth (the cognitive resources needed for decisions), thus undermining behaviors like daily medication adherence and service engagement. To address these gaps, the study's objective is to rigorously test whether and how economic scarcity affects medication adherence and preventive service uptake among older adults with chronic disease, leveraging the naturally occurring monthly fluctuation in scarcity created by the Supplemental Nutrition Assistance Program (SNAP) benefit cycle as a natural experiment. There are three aims: 1. Daily medication adherence will be measured objectively for four months with wireless electronic pill bottle caps (CleverCaps). The investigators will test whether, when, and by how much adherence changes as scarcity fluctuates during the SNAP benefit cycle. 2. The investigators will conduct two easily implementable RCTs to test whether scarcity affects participants' engagement with beneficial services requiring navigation of administrative burdens. In one trial, participants will be randomized to receive an invitation during either a high- or low- scarcity period (i.e., before vs. after SNAP receipt) to a personalized preventive health review that identifies gaps in US Preventive Services Task Force Grade A/B recommendations. In the second, participants will be invited to free financial counseling provided by the City of Philadelphia during a high- or low-scarcity period. The investigators hypothesize invitation response rates will be \>15% higher during low-scarcity periods. 3. Potential mechanisms that link scarcity with health behaviors will be examined by randomizing timing of validated measures of mental bandwidth and future orientation during a period of high- or low-scarcity (i.e., before vs. after SNAP receipt). The investigators hypothesize that there will be differences in several measures between participants who are randomly assessed during high- vs. low-scarcity periods (i.e. before vs. after SNAP receipt). Impact: Demonstrating that scarcity helps to explain low medication adherence and beneficial health-related service uptake can inform patient-centered adherence interventions, clinical care-delivery approaches, health-system strategies, and public health approaches to improve these health behaviors and promote healthy aging.

Waitlist Available
Has No Placebo

Penn Medicine, 3535 Market St.

Image of Lake Havasu Unified School District in Lake Havasu City, United States.

Nutrition and Fitness Program for Schoolchildren's Health

9 - 14
All Sexes
Lake Havasu City, AZ

The goal of this clinical trial is to learn if a school-based intervention, Operation ToneUp, can improve nutrition knowledge, fitness, and blood pressure in schoolchildren enrolled in grades 3-6. The main questions it aims to answer are: 1. Do students participating in the intervention show improved fitness, measured by upper body strength, core strength, and cardiovascular endurance? 2. Do students participating in the intervention show improved nutrition knowledge, measured by self-report? 3. Do students participating in the intervention show improved blood pressure, measured by blood pressure cuff? Researchers will compare students participating in the intervention to students at comparison schools to see if fitness, nutrition knowledge, and blood pressure differ. Participants in the intervention arm will complete two 20-minute web-based sessions focused on nutrition and fitness during class time. Participants in the comparison arm will not be exposed to Operation ToneUp. All participants will engage in pre- and post- testing including: * PE-teacher assessed push-ups, curl-ups, and PACER test * online self-reported nutrition knowledge assessments * nurse-recorded blood pressure

Waitlist Available
Has No Placebo

Lake Havasu Unified School District

Allison Poulos, PhD

Have you considered Rybelsus clinical trials?

We made a collection of clinical trials featuring Rybelsus, we think they might fit your search criteria.
Go to Trials